BPaLM regimen in India: A remarkable step towards tuberculosis elimination

---

Perspective

Author Details : Sankalp Yadav*, Naveen Jeyaraman, Madhan Jeyaraman, Gautam Rawal

Volume : 9, Issue : 3, Year : 2024

Article Page : 117-118

https://doi.org/10.18231/j.ijirm.2024.024

Suggest article by email

Get Permission

---

Abstract

India is having a high burden of drug-resistant tuberculosis. In a country with overwhelmed health facilities, it is a challenging task to address issues related to tuberculosis elimination. Further, India aims to achieve the global target of tuberculosis elimination by 2025, which is five years earlier than the global target. To achieve this uphill target, there is a constant need to improve the management of tuberculosis. One such latest development is the introduction of bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM)-based regimens to fight against multidrug-resistant tuberculosis. The present article sheds light on this new treatment rolled out by the Government of India.
 

Keywords: MDR/RR-TB, DR-TB, Treatment guidelines, Shorter regimen, Longer regimens

How to cite : Yadav S, Jeyaraman N, Jeyaraman M, Rawal G, BPaLM regimen in India: A remarkable step towards tuberculosis elimination. IP Indian J Immunol Respir Med 2024;9(3):117-118

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.